Skye Bioscience names John P. Sharp CFO

Skye Bioscience, Inc.

SKYE

0.00

Skye Bioscience appointed John P. Sharp as chief financial officer, effective March 31, 2026.
Sharp currently serves as senior director at Lohman & Associates.
His prior CFO roles include SaNOtize Research and Development Corp. and PhaseBio Pharmaceuticals.
Skye Bioscience also repriced employee stock options granted before Dec. 31, 2025, cutting exercise prices to $0.615 per share.
Options covering 2,420,978 shares were repriced, including 1,103,959 options held by CEO Punit Dhillon and 396,295 held by COO Tuan Diep.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-023699), on April 03, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.